{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-027426","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2023-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.642166+00:00","generated_at":"2026-06-12T06:03:06.800262+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ovid Therapeutics Q2 net loss $12.4M; OV329 SAD complete; Graviton ROCK2 collaboration","bullets":["Cash and securities $96.5M as of June 30, 2023; net loss $0.18 per share vs $0.21 year ago.","OV329 Phase 1 single-ascending-dose portion completed with no safety signals; full data expected H1 2024.","Entered license/collaboration with Graviton for ROCK2 inhibitors with $10M equity investment.","Appointed Dr. Zhong Zhong CSO and Dr. Manoj Malhotra CMO; Meg Alexander promoted to Chief Strategy Officer.","Implemented cost-cutting measures including G&A headcount reduction; cash runway expected into 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-027426","json":"https://secwatch.observer/filing/0001628280-23-027426.json","markdown":"https://secwatch.observer/filing/0001628280-23-027426.md","text":"https://secwatch.observer/filing/0001628280-23-027426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828023027426/0001628280-23-027426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828023027426/ovid-20230804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T06:03:06.800262+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4bf80fdb3f6f991c23e115f3612cefda20b16af6","claim":"Ovid Therapeutics Inc. reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"On August 4, 2023, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Second Quarter 2023 Financial Results and Corporate Updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000162828023027426/0001628280-23-027426-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}